We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y
Read MoreHide Full Article
Nevro Corp. (NVRO - Free Report) reported fourth-quarter 2019 loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. The company had incurred a loss of 32 cents in the year-ago quarter.
For 2019, Nevro Corp.’s loss per share was $3.37, narrower than the Zacks Consensus Estimate of a loss of $3.46. This compares to the year-ago quarter’s loss of $1.64.
The Zacks Rank #1 (Strong Buy) company posted revenues of $114.4 million, which surpassed the Zacks Consensus Estimate by 3.2%. The figure also rose 6% year over year.
Revenues in 2019 totaled $390.3 million, up 0.8%. The metric surpassed the Zacks Consensus Estimate of $387.4 million.
Quarter Highlights
In the quarter under review, international revenues were $16.5 million, up 1% year over year and 3% at constant currency.
U.S. revenues for the quarter totaled $97.9 million, up 7% year over year. Per management, revenues gained from the 17% year-over-year growth in U.S. trials and 20% increase in permanent implant.
Gross profit totaled $81.3 million, up 6.7% year over year. Gross margin was 71%, up 50 basis points.
Operating expenses rose 9.7% year over year to $92.9 million. Research and development expenses totaled $16.9 million, up 25.6%.
Sales, general and administrative expenses rose 6.6% to $76 million.
Loss from operations was $11.7 million, compared with a loss of $8.6 million in the year-ago quarter.
Guidance
Nevro Corp. expects 2020 revenues within $435-$440 million. The Zacks Consensus Estimate for the same is pegged at $437.9 million.
Gross margin is projected in the range of 69-70% and operating expenses are expected at around $355 million.
Summary
Nevro Corp exited the fourth quarter on a strong note. The company’s domestic and international revenues surged on a year-over-year basis. Also, demand for implants drove the solid quarterly show. The commercial launch of the Senza Omnia SCS System buoys optimism. A strong guidance for 2020 holds promise. Expansion in gross margin is heartening.
On the flip side, increased operating expenses raise concern.
Stryker reported fourth-quarter 2019 adjusted earnings per share (EPS) of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y
Nevro Corp. (NVRO - Free Report) reported fourth-quarter 2019 loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. The company had incurred a loss of 32 cents in the year-ago quarter.
For 2019, Nevro Corp.’s loss per share was $3.37, narrower than the Zacks Consensus Estimate of a loss of $3.46. This compares to the year-ago quarter’s loss of $1.64.
The Zacks Rank #1 (Strong Buy) company posted revenues of $114.4 million, which surpassed the Zacks Consensus Estimate by 3.2%. The figure also rose 6% year over year.
Revenues in 2019 totaled $390.3 million, up 0.8%. The metric surpassed the Zacks Consensus Estimate of $387.4 million.
Quarter Highlights
In the quarter under review, international revenues were $16.5 million, up 1% year over year and 3% at constant currency.
U.S. revenues for the quarter totaled $97.9 million, up 7% year over year. Per management, revenues gained from the 17% year-over-year growth in U.S. trials and 20% increase in permanent implant.
Nevro Corp. Price, Consensus and EPS Surprise
Nevro Corp. price-consensus-eps-surprise-chart | Nevro Corp. Quote
Margins
Gross profit totaled $81.3 million, up 6.7% year over year. Gross margin was 71%, up 50 basis points.
Operating expenses rose 9.7% year over year to $92.9 million. Research and development expenses totaled $16.9 million, up 25.6%.
Sales, general and administrative expenses rose 6.6% to $76 million.
Loss from operations was $11.7 million, compared with a loss of $8.6 million in the year-ago quarter.
Guidance
Nevro Corp. expects 2020 revenues within $435-$440 million. The Zacks Consensus Estimate for the same is pegged at $437.9 million.
Gross margin is projected in the range of 69-70% and operating expenses are expected at around $355 million.
Summary
Nevro Corp exited the fourth quarter on a strong note. The company’s domestic and international revenues surged on a year-over-year basis. Also, demand for implants drove the solid quarterly show. The commercial launch of the Senza Omnia SCS System buoys optimism. A strong guidance for 2020 holds promise. Expansion in gross margin is heartening.
On the flip side, increased operating expenses raise concern.
Earnings of Other MedTech Majors at a Glance
Other top-ranked companies, which reported solid results this earnings season, include Stryker Corporation (SYK - Free Report) , Accuray Incorporated (ARAY - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker reported fourth-quarter 2019 adjusted earnings per share (EPS) of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Revenues of $4.13 billion surpassed the consensus estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>